10x Genomics, Inc. (TXG)
- Sector
- Life Sciences Tools & Services
- Last price
- $83.62
- As of
Kresmion compiles this page from TXG's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
10x Genomics, Inc. (TXG): 7 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-08-07.
See the full TXG dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for TXG on one page. Preview it with sample data, then open it live with a free account.
Preview the TXG dossierActive events for TXG
- high13F: funds reduced
3 tracked funds reduced TXG this 2026Q2, institutional consensus
- high13F: funds added
4 tracked funds increased TXG this 2026Q2, institutional consensus
- high13F: funds added
3 tracked funds increased TXG this 2026Q2, institutional consensus
- high13F: large increase
CITADEL ADVISORS LLC added +251% to TXG (2026Q2)
- high13F: large increase
CITADEL ADVISORS LLC added +1330% to TXG (2026Q2)
FREE, NO ACCOUNT
Every event on TXG, as it fires
You are seeing 5 of 23 events recorded on TXG since 2026-06-05.
The five above landed across 2 days. The other 18 were recorded on 4 other days. 13 of the 23 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in TXG (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| CITADEL ADVISORS LLCCUSIP 88025U109 · 2026Q2 | $106.6M | 0.01% | , |
| Point72 Asset Management, L.P.CUSIP 88025U109 · 2026Q2 | $71M | 0.08% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 88025U109 · 2026Q2 | $30.8M | 0.04% | , |
| D. E. Shaw & Co., Inc.CUSIP 88025U109 · 2026Q2 | $8.9M | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 88025U109 · 2026Q2 | $5.4M | 0.00% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 88025U109 · 2026Q2 | $4.5M | 0.00% | , |
| Bridgewater Associates, LPCUSIP 88025U109 · 2026Q2 | $513K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, TXG
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
TXG against its peers
TXG's operating margin of -9.5% ranks in the 44th percentile of 23 Life Sciences Tools & Services sub-industry peers, fiscal periods ending between 2025-10-31 and 2026-06-30.
| Metric | TXG | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 643M USD | 1.3B USD | 37 | 25 |
| Gross margin | 69.1% | 55.5% | 91 | 15 |
| Operating margin | -9.5% | 0.6% | 44 | 23 |
| Net margin | -6.8% | -0.3% | 44 | 25 |
| Return on equity | -5.5% | -2.5% | 46 | 24 |
| P / E | n/a | 45.8x | n/a | 12 |
| 1 year | n/a | 26.3% | n/a | 7 |
Peers (25): AVTR, TECH, RGEN, BRKR, TEM, CRL, MEDP, SHC, ADPT, ABCL, MTD, ILMN, IQV, WAT, FTRE, A, MRVI, CTKB, DHR, MLAB, OABI, DNA, PACB, TMO, MXCT. Fiscal periods ending between 2025-10-31 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (TXG: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow TXG on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to TXG for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.